Curaleaf Responds To FDA Warning Letter


Earlier this week, the Meals and Drug Administration (FDA) issued a warning letter to Massachusetts-based, multi-state cannabis operator Curaleaf Holdings, Inc. to advise the corporate that a number of the advertising and marketing for cannabidiol (CBD) merchandise on its web site and social media pages was in violation of the Meals, Drug, and Beauty (FD&C) Act and FDA rules

Curaleaf responded to the FDA on Thursday, informing the company that the problems introduced within the letter had been addressed.

Upon receipt of the FDA warning letter, Curaleaf Hemp carried out a full assessment of its web site and social media platforms to take away non-compliant statements and claims in regards to the firm’s merchandise.

The corporate additionally eliminated the Curaleaf Hemp weblog and took down all third celebration hyperlinks in it.

In keeping with Curaleaf, a number of the merchandise that had been listed within the FDA warning letter had been beforehand discontinued.

“We care deeply about our prospects and making a distinction in our trade,” stated Curaleaf CEO Joseph Lusardi in a press release. “Curaleaf is dedicated to being an moral and accountable firm and dealing with the FDA to be a pacesetter in our trade, setting the requirements and pointers to greatest service our prospects and the communities we serve.”

Lusardi says that the trade wants, desires, and appreciates the work that the FDA is doing to make sure regulation and compliance within the CBD market.



Latest posts